<DOC>
	<DOCNO>NCT02618512</DOCNO>
	<brief_summary>This study evaluate safety tolerability intravenous ( IV ) administration SBC-103 previously study , SBC-103 treatment naïve patient mucopolysaccharidosis III , type B ( MPS IIIB , Sanfilippo B ) participate NGLU-CL01 study . The NGLU-CL01 study non-interventional study evaluate structural brain abnormality blood brain barrier ( BBB ) integrity magnetic resonance imaging ( MRI ) cerebrospinal fluid/serum albumin index .</brief_summary>
	<brief_title>A Open Label Study Previously Studied , SBC-103 Treatment Naïve MPS IIIB Subjects Investigate Safety , Pharmacokinetics , Pharmacodynamics/Efficacy SBC-103 Administered Intravenously</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<criteria>Previous participation NGLUCL01 study . Received treatment gene therapy time , investigational drug device intend treatment MPS IIIB within 30 day prior Screening , currently treat another study involve investigational drug device . Previous hematopoietic stem cell bone marrow transplant . Has internal nonremovable external metal item may present safety risk study assessment utilize magnetic field , medical condition circumstance MRI contraindicate accord local institutional policy . Known hypersensitivity egg .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>